TGFB1 and hepatitis C virus infection: Corilagin has also been reported to cause the release of TNF-α inhibitor in inflammation [39], decrease the secretion of the transforming growth factor beta 1 (TGF-β1) in a dose dependent manner [31], and inhibit hepatitis C viral replication in vitro [40].